Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
45 hedge funds and large institutions have $14.1M invested in Sierra Oncology, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 7 closing their positions.
8% less funds holding
Funds holding: 49 → 45 (-4)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
35% less capital invested
Capital invested by funds: $21.9M → $14.1M (-$7.74M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$153K |
| 2 |
WG
Winton Group
London,
United Kingdom
|
+$122K |
| 3 |
6CM
683 Capital Management
New York
|
+$120K |
| 4 |
HP
Hikari Power
Tokyo,
Japan
|
+$119K |
| 5 |
Two Sigma Advisers
New York
|
+$41.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.36M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$415K |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$151K |
| 4 |
SIM
Spark Investment Management
New York
|
-$99.2K |
| 5 |
VF
Virtu Financial
New York
|
-$67K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Morgan Stanley
New York
| – | -$957 | -50 | -82% |
|
52
Barclays
London,
United Kingdom
| – | -$96 | -5 | -63% |
|
SRRA Hedge Fund Activity: Q3 2019 in Review
45 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q3 2019, worth a combined $14.1M — down 35% from $21.9M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SRRA and 4 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 10 added.
The largest buyer was Renaissance Technologies, adding an estimated $153K. The largest seller was Vivo Capital, exiting entirely with an estimated $1.36M sold.
- 45 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q3 2019, down from 49 in Q2 2019.
- Funds reported $14.1M of Sierra Oncology, Inc. Common Stock stock for Q3 2019, down 35% quarter-over-quarter.
- 4 funds opened new Sierra Oncology, Inc. Common Stock positions in Q3 2019 and 7 closed out, a net change of -3 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q3 2019 was Renaissance Technologies, an estimated $153K added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q3 2019 was Vivo Capital, an estimated $1.36M sold.
Based on aggregated 13F filings for Q3 2019.